Oriana H Y Yu
Overview
Explore the profile of Oriana H Y Yu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
250
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moiz A, Filion K, Toutounchi H, Tsoukas M, Yu O, Peters T, et al.
Ann Intern Med
. 2025 Jan;
178(2):199-217.
PMID: 39761578
Background: Recent randomized controlled trials (RCTs) have investigated glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual or triple co-agonists for weight loss among adults with overweight or obesity and without...
2.
Yu Y, Platt R, Reynier P, Yu O, Filion K
Diabetes Obes Metab
. 2024 Dec;
27(2):976-986.
PMID: 39676749
Aims: Metformin is increasingly used off-label as the treatment of gestational diabetes (GDM). Our objective was to determine if metformin versus insulin initiation is associated with the adverse pregnancy outcomes....
3.
Shapiro S, Yin H, Yu O, Azoulay L
Drug Saf
. 2024 May;
47(8):759-769.
PMID: 38720114
Introduction: The use of dipeptidyl peptidase-4 (DPP-4) inhibitors may be associated with an increased risk of gallbladder and bile duct disease among patients with type 2 diabetes. Methods: We conducted...
4.
Shapiro S, Yin H, Yu O, Azoulay L
Br J Clin Pharmacol
. 2024 Mar;
90(5):1365-1370.
PMID: 38477518
We sought to determine whether the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors is associated with a decreased risk of incident lung cancers among patients with type 2 diabetes. We assembled...
5.
Igweokpala S, Sule N, Douros A, Yu O, Filion K
Diabetes Obes Metab
. 2023 Nov;
26(2):721-731.
PMID: 38031234
Aim: The results from the SUSTAIN-6 trial generated some uncertainty regarding the association between incretin-based drugs [dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs)] and the risk...
6.
Pradhan R, Yu O, Platt R, Azoulay L
BMJ Open Diabetes Res Care
. 2023 Nov;
11(6).
PMID: 37949470
Introduction: The dipeptidyl peptidase-4 (DPP-4) enzyme significantly influences carcinogenic pathways in the skin. The objective of this study was to determine whether DPP-4 inhibitors are associated with the incidence of...
7.
Grandi S, Yu Y, Reynier P, Platt R, Yu O, Filion K
Paediatr Perinat Epidemiol
. 2023 Nov;
38(6):470-481.
PMID: 37921423
Background: While the benefits of levothyroxine are well-established for overt hypothyroidism, they are unclear for subclinical hypothyroidism (SCH) among pregnant women. Objective: To estimate the effect of initiation of levothyroxine...
8.
Pradhan R, Yu O, Platt R, Azoulay L
Diabet Med
. 2023 Oct;
41(4):e15248.
PMID: 37876318
Aims: The objective of this study was to determine whether the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased risk of melanoma and nonmelanoma skin...
9.
Park S, Jeong H, Bea S, Yu O, Cho Y, Chan You S, et al.
Diabetes Obes Metab
. 2023 Jul;
25(11):3248-3258.
PMID: 37503763
Aim: To assess the risk of amputation associated with sodium-glucose co-transporter-2 inhibitors (SGLT2is) among patients with type 2 diabetes, across categories of baseline cardiovascular disease (CVD) and diuretic use (DU)....
10.
Aloe S, Filliter C, Salmasi S, Igweokpala S, Yu O, Tagalakis V, et al.
Br J Clin Pharmacol
. 2023 May;
89(9):2902-2914.
PMID: 37183930
Aims: The cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2Is) result from their complex impact on coronary and arterial vessels. However, their effect on veins and the risk of venous...